The global clinical chemistry analyzers market is expected to reach USD 21,308.36 million by 2027, growing at a CAGR of 7.5 percent during 2020-2027. The growing prevalence of chronic diseases is anticipated to be responsible for the high urgency to adopt clinical chemistry analyzers, which thereby widens the scope for growth during the forecast period. In addition, growing base of geriatric and bariatric population, which is highly susceptible to chronic diseases, is presumed to impel the demand further. Consequently, the resultant high sample volume requiring high capability analyzing devices is driving the market growth.
Moreover, increasing awareness pertaining to benefits associated with these devices is also a high impact rendering driver for clinical chemistry analyzers market. Advent of advanced chemistry analyzers has resulted in improved point-of-care testing capabilities, and thus created high potential growth opportunities for the market. In addition, technological advancements in preanalytical, analytical, and post analytical stages due to analyzing devices & reagents improved their diagnostic capabilities and overall efficiency, which is predicted to propel the growth further. These advancements include advent of microchips, sensors, chemometrics, and robotics. Furthermore, consistent efforts by public as well private healthcare organizations to increase the reliability of data have rapidly engendered the integration of automated chemistry analyzers and immunoassay systems, thereby resulting in overall reduction of workload in laboratories, thus propelling the demand.
Some of the key players in clinical chemistry analyzers market include Siemens Healthineers, Thermo Fisher Scientific, Inc, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Randox Laboratories Ltd, Mindray Medical International Limited, Ortho Clinical Diagnostics, Danaher Corporation, Horiba Ltd, and Elitech Group.